Randomized Parallel-Group Phase II Study (NEOTERIC) of Atezolizumab With or Without Tiragolumab After Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer
In patients with LARC, Atezo + Tira after nCRT statistically improved the pCR rate compared with historical controls, with an acceptable safety profile.
Authors
- Xianrui Wu (ORCID: https://orcid.org/0009-0002-4856-4115)
- Tong Li (ORCID: https://orcid.org/0000-0003-1525-8971)
- N. Chen
- Funan Liu (ORCID: https://orcid.org/0000-0003-4762-8279)
- Wentao Tang (ORCID: https://orcid.org/0000-0002-8281-7588)
- Ping Lan (ORCID: https://orcid.org/0000-0001-5206-5533)
- Kefeng Ding
- Y. Shi
- Aiwen Wu
- Yurong Jiao
- Jianmin Xu
- Jian Wang
- Zhenning Wang
Institutions
- Sun Yat-sen University (CN)
- Peking University (CN)
- Fudan University (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Peking University Cancer Hospital (CN)
- Roche (China) (CN)
- Zhongshan Hospital (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- First Hospital of China Medical University (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
- China Medical University (CN)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1200/jco-25-01883
- Primary Topic
- Colorectal Cancer Surgical Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00